

Myrbetriq[®] (mirabegron) – First-time generic launch halted

- On April 23, 2024, the Federal Circuit court issued a temporary injunction halting Lupin and Zydus launch of AB-rated generic versions of Astellas' [Myrbetriq \(mirabegron\)](#) 25 mg extended-release tablets.
- Myrbetriq is approved for the following:
 - Treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency
 - In combination with [solifenacin succinate](#), for the treatment of OAB in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency
 - Treatment of neurogenic detrusor overactivity in pediatric patients aged 3 years and older and weighing 35 kg or more.